Gain Therapeutics to Participate at BTIG Virtual Biotechnology Conference
Maxim Group Maintains Gain Therapeutics(GANX.US) With Buy Rating
Optimistic Outlook for Gain Therapeutics Amid Progress of GT-02287 and Successful Financing
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Maintains Target Price $8
Express News | HC Wainwright & Co. Reiterates Buy on Gain Therapeutics, Maintains $8 Price Target
Analysts Offer Insights on Healthcare Companies: Hims & Hers Health (HIMS) and Gain Therapeutics (GANX)
Express News | Gain Therapeutics Inc : Maxim Group Cuts Target Price to $5 From $10
Gain Therapeutics Advances Parkinson's Treatment in Phase 1
Gain Therapeutics Advances Parkinson's Therapy With Successful Phase 1 Results for GT-02287
Express News | Gain Therapeutics Inc - No Discontinuations or Serious Adverse Events Reported
Express News | Gain Therapeutics Inc - GT-02287 Trial in Parkinson's Disease Patients in Q4 2024
Express News | Gain Therapeutics Inc - Topline Data to Be Presented Mid-August
Express News | Gain Therapeutics Inc - GT-02287 Well Tolerated With No Serious Adverse Events
Express News | Gain Therapeutics Announces the Completion of Dosing in the Multiple Ascending Dose (Mad) of the Phase 1 Study of GT-02287, a Novel Small Molecule Therapy for Parkinson’s Disease
12 Health Care Stocks Moving In Thursday's Pre-Market Session
H.C. Wainwright Maintains Gain Therapeutics(GANX.US) With Buy Rating, Cuts Target Price to $8
Gain Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Gain Therapeutics Analyst Ratings
Express News | Gain Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $8 From $9
Gain Therapeutics(GANX.US) Director Buys US$20,670 in Common Stock